Last week, the company updated its revenue guidance to $72 million to $74 million for FY 2015.
EndoChoice stock has a 52-week high of $19.69 and a 52-week low of $7.37, according to the report.
More articles on gastroenterology:
Exact Sciences to open biotech campus & more – 3 GI company key notes
CMS cuts to colonoscopy reimbursement finalized: 3 things to know
6 recent must-reads on CRC screening & treatments
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.